Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Wegovy weight-loss jab to launch in the UK

The drug is in short supply but a proportion has been allocated to specialist NHS services

Evening Standard

The history of weight loss drugs

"It is no wonder demand for weight-loss drugs continues to soar"

Salon

Novo Nordisk: the pharma giant making Denmark rich from US obesity epidemic

Soaring demand for two weight-loss wonder-drugs developed by a Danish pharmaceutical company is having a knock-on effect on the whole of Denmark’s economy.

The Week

From analysis to the latest developments in health,
read the most diverse news in one place.

How Novo Nordisk, A Top 1% Stock, Just Hit Another Bull's-eye In Obesity Treatment

Novo Nordisk said Friday its obesity treatment, Wegovy, reduced heart-failure symptoms. But Novo Nordisk stock remained flat.

Investors Business Daily

Why This Nugget Of Bad Weight-Loss News Isn't Weighing On Lilly, Novo

Prescriptions of weight-loss and diabetes drugs have rocketed this year, giving Novo Nordisk stock and Eli Lilly stock more room to run.

Investors Business Daily

Insulin Patients Can Find Discounts With Amazon's New Automated Coupon System

Amazon Pharmacy will automatically apply manufacturer-sponsored coupons for 15-plus products.

Kiplinger

A pharma company helping Elon Musk shed weight is now worth more than the entire economy of Denmark

The weight-loss and diabetes injectables have seen a surge in demand primarily in the U.S., buoying Novo Nordisk’s profits in the first half of 2023.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Market Rally On The Ropes, AI Stocks Tumble: Weekly Review

The market rally suffered more damage as the Nasdaq undercut key support and many leading AI stocks sold off hard.

Investors Business Daily

Novo Reverses Obesity-Related Winning Streak, Diving On Light Sales

Novo is restricting some doses of Wegovy in the U.S., the company said Thursday. Novo Nordisk stock fell on light second-quarter sales.

Investors Business Daily

Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?

Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?

Investors Business Daily

Weight-loss jabs can cut risk of heart attacks or strokes

Risk of heart attack or stroke cut by fifth, researchers say

The Independent UK

Dow Jones Futures Rise After Market Rally Holds Support; Two Big AI Losers

The market rally faces a key test. Nvidia is holding strong, but some Magnificent 7 stocks are ailing. Two AI plays dived late.

Investors Business Daily

Stock Market Today: Stocks Drop on Troubling China Data, Bank Ratings Worries

The main benchmarks fell Tuesday, but healthcare stocks outperformed as Eli Lilly and Novo Nordisk surged.

Kiplinger

Ozempic is in the spotlight but it's just the latest in a long and strange history of weight-loss drugs

Losing weight conveniently, cheaply, safely. That’s been the holy grail of weight-loss ever since 19th century English undertaker and weight-loss celebrity William Banting’s 1863 Letter on Corpulence spruiked his “miraculous” method of slimming down.

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

The drug “has the potential to change how obesity is regarded and treated,” the company's executive vice president for development says.

The Guardian - UK

Weight-loss jab can cut heart attack and stroke risk in obese adults, firm says

Wegovy manufacturer says five-year study found drug reduced major cardiovascular events by 20% in overweight or obese people

Investors Business Daily

Why The Weight-Loss Bonanza Catapulted Lilly And Novo, But Hammered Dexcom And Others

Novo Nordisk stock surged Tuesday after the firm said its weight-loss drug reduced the risk of cardiovascular events.

The Independent UK

Weight loss jabs can cut risk of heart attack or stroke by fifth, study suggests

The trial involved more than 17,600 people from across 41 countries.

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.

The Independent UK

Nearly half of US adults are interested in taking weight loss prescription drugs, survey finds

Ozempic, a once-weekly semaglutide injection, has grown in popularity for its weight loss side effects

Fortune

Novo Nordisk developed Ozempic and started a weight-loss revolution. Its next moonshot is eliminating obesity altogether

Novo’s Ozepmic and Wegovy drugs have altered the mission of the 100-year-old Danish pharma firm best known—until now—for insulin.

Zenger

Ozempic And Wegovy Side Effects Prompt Safety Concerns For Novo Nordisk

Stomach paralysis risk raises concerns over popular weight loss and diabetes drugs

The Guardian - UK

Weight-loss drugs under review in UK after reports of suicidal thoughts

Ozempic and Saxenda among drugs being reviewed after five reports of suspected adverse reactions in patients

The Independent UK

Ozempic users report stomach paralysis as weight loss drug side effect: ‘I wish I never touched it’

The FDA has received reports of stomach paralysis among patients taking Ozempic and Wegovy

The Conversation

The obesity epidemic is fuelled by biology, not lack of willpower

Since the time a human first used a tool to make life easier, increased weight has been inevitable.

1 … 20 21 22 23

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.